

Xandra O Breakefield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/495722/publications.pdf>

Version: 2024-02-01

319
papers

50,347
citations

2101

100
h-index

1676

214
g-index

320
all docs

320
docs citations

320
times ranked

43124
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
2	Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology, 2008, 10, 1470-1476.	10.3	4,285
3	Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews Drug Discovery, 2013, 12, 347-357.	46.4	2,563
4	Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cellular and Molecular Neurobiology, 2016, 36, 301-312.	3.3	1,168
5	Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends in Cell Biology, 2017, 27, 172-188.	7.9	1,087
6	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. PLoS Biology, 2012, 10, e1001450.	5.6	1,064
7	The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics, 1997, 17, 40-48.	21.4	1,051
8	New Technologies for Analysis of Extracellular Vesicles. Chemical Reviews, 2018, 118, 1917-1950.	47.7	1,041
9	RNA delivery by extracellular vesicles in mammalian cells and its applications. Nature Reviews Molecular Cell Biology, 2020, 21, 585-606.	37.0	1,010
10	Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nature Communications, 2011, 2, 180.	12.8	974
11	Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. BioScience, 2015, 65, 783-797.	4.9	813
12	Dynamic Biodistribution of Extracellular Vesicles <i>in Vivo</i> Using a Multimodal Imaging Reporter. ACS Nano, 2014, 8, 483-494.	14.6	663
13	Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine, 2012, 18, 1835-1840.	30.7	647
14	Codon-Optimized Gaussia Luciferase cDNA for Mammalian Gene Expression in Culture and in Vivo. Molecular Therapy, 2005, 11, 435-443.	8.2	635
15	Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 2019, 11, .	12.4	595
16	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nature Communications, 2015, 6, 6999.	12.8	484
17	Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab on A Chip, 2010, 10, 505-511.	6.0	462
18	Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications, 2015, 6, 7029.	12.8	449

#	ARTICLE	IF	CITATIONS
19	miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells. <i>Cancer Cell</i> , 2008, 14, 382-393.	16.8	441
20	Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. <i>Nature Genetics</i> , 1995, 9, 152-159.	21.4	430
21	The pathophysiological basis of dystonias. <i>Nature Reviews Neuroscience</i> , 2008, 9, 222-234.	10.2	420
22	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	10.3	416
23	Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 439-464.	9.4	415
24	Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. <i>Nature Communications</i> , 2017, 8, 1145.	12.8	384
25	Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector. <i>Cancer Research</i> , 2006, 66, 2509-2513.	0.9	363
26	Multidimensional communication in the microenvirons of glioblastoma. <i>Nature Reviews Neurology</i> , 2018, 14, 482-495.	10.1	357
27	Extracellular vesicles: emerging targets for cancer therapy. <i>Trends in Molecular Medicine</i> , 2014, 20, 385-393.	6.7	349
28	TorsinA and heat shock proteins act as molecular chaperones: suppression of α -synuclein aggregation. <i>Journal of Neurochemistry</i> , 2002, 83, 846-854.	3.9	318
29	Viral vectors for gene delivery to the nervous system. <i>Nature Reviews Neuroscience</i> , 2003, 4, 353-364.	10.2	292
30	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	5.1	284
31	Genetically Engineered Microvesicles Carrying Suicide mRNA/Protein Inhibit Schwannoma Tumor Growth. <i>Molecular Therapy</i> , 2013, 21, 101-108.	8.2	282
32	miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. <i>PLoS ONE</i> , 2013, 8, e78115.	2.5	270
33	A secreted luciferase for ex vivo monitoring of in vivo processes. <i>Nature Methods</i> , 2008, 5, 171-173.	19.0	263
34	SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. <i>Science</i> , 2016, 352, 242-246.	12.6	259
35	High levels of AAV vector integration into CRISPR-induced DNA breaks. <i>Nature Communications</i> , 2019, 10, 4439.	12.8	257
36	Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. <i>NeuroReport</i> , 1993, 4, 367-370.	1.2	256

#	ARTICLE	IF	CITATIONS
37	Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano, 2018, 12, 494-503.	14.6	256
38	Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications, 2018, 9, 175.	12.8	248
39	Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. Annals of Neurology, 2000, 48, 65-71.	5.3	247
40	Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron, 1989, 2, 1427-1434.	8.1	246
41	Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro-Oncology, 2016, 18, 58-69.	1.2	245
42	Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/ β -Catenin Signaling Pathway. Molecular and Cellular Biology, 2009, 29, 5923-5940.	2.3	240
43	Microvesicle-associated AAV Vector as a Novel Gene Delivery System. Molecular Therapy, 2012, 20, 960-971.	8.2	236
44	miR-1289 and "Zipcode" like Sequence Enrich mRNAs in Microvesicles. Molecular Therapy - Nucleic Acids, 2012, 1, e10.	5.1	235
45	From The Cover: TorsinA in the nuclear envelope. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7612-7617.	7.1	225
46	Emerging Roles of Extracellular Vesicles in the Nervous System. Journal of Neuroscience, 2014, 34, 15482-15489.	3.6	219
47	Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell, 2019, 177, 446-462.e16.	28.9	214
48	<i>In Vivo</i> Tracking of Neural Progenitor Cell Migration to Glioblastomas. Human Gene Therapy, 2003, 14, 1247-1254.	2.7	210
49	Herpes Simplex Virus Type 1 DNA Amplified as Bacterial Artificial Chromosome in <i>Escherichia coli</i> : Rescue of Replication-Competent Virus Progeny and Packaging of Amplicon Vectors. Human Gene Therapy, 1998, 9, 2787-2794.	2.7	209
50	Improved Helper Virus-Free Packaging System for HSV Amplicon Vectors Using an ICP27-Deleted, Oversized HSV-1 DNA in a Bacterial Artificial Chromosome. Molecular Therapy, 2001, 3, 591-601.	8.2	200
51	Prodrug activation enzymes in cancer gene therapy. Journal of Gene Medicine, 2000, 2, 148-164.	2.8	191
52	Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics, 2000, 9, 1403-1413.	2.9	190
53	Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology, 2005, 57, 34-41.	5.3	188
54	Extracellular vesicles and intercellular communication within the nervous system. Journal of Clinical Investigation, 2016, 126, 1198-1207.	8.2	188

#	ARTICLE	IF	CITATIONS
55	Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. <i>Molecular Therapy</i> , 2017, 25, 379-391.	8.2	181
56	Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation. <i>Annals of Neurology</i> , 1994, 36, 771-777.	5.3	176
57	RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. <i>BMC Cancer</i> , 2012, 12, 22.	2.6	176
58	Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. <i>Neuro-Oncology</i> , 2017, 19, 1494-1502.	1.2	168
59	Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. <i>Cell</i> , 2018, 172, 897-909.e21.	28.9	163
60	Intravascular Delivery of Neural Stem Cell Lines to Target Intracranial and Extracranial Tumors of Neural and Non-Neural Origin. <i>Human Gene Therapy</i> , 2003, 14, 1777-1785.	2.7	162
61	Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus Vectors. <i>Human Gene Therapy</i> , 1994, 5, 183-191.	2.7	160
62	TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. <i>Journal of Cell Science</i> , 2008, 121, 3476-3486.	2.0	159
63	Heparin blocks transfer of extracellular vesicles between donor and recipient cells. <i>Journal of Neuro-Oncology</i> , 2013, 115, 343-351.	2.9	156
64	Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. <i>Neurogenetics</i> , 2001, 3, 133-143.	1.4	155
65	Heparin affinity purification of extracellular vesicles. <i>Scientific Reports</i> , 2015, 5, 10266.	3.3	152
66	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	28.9	152
67	Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas. <i>Molecular Therapy</i> , 2000, 1, 347-357.	8.2	151
68	FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. <i>Journal of Clinical Investigation</i> , 2003, 112, 1202-1210.	8.2	151
69	Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis. <i>Nature Genetics</i> , 1993, 4, 160-164.	21.4	149
70	TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. <i>Neurobiology of Disease</i> , 2003, 12, 11-24.	4.4	148
71	Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. <i>Annals of Neurology</i> , 2002, 51, 621-625.	5.3	147
72	HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells. <i>Human Gene Therapy</i> , 1997, 8, 359-370.	2.7	146

#	ARTICLE	IF	CITATIONS
73	Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene. <i>Human Gene Therapy</i> , 1994, 5, 969-978.	2.7	144
74	Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. <i>Brain Research</i> , 1995, 691, 25-36.	2.2	143
75	The TOR1A (DYT1) Gene Family and Its Role in Early Onset Torsion Dystonia. <i>Genomics</i> , 1999, 62, 377-384.	2.9	142
76	miRNA-7 Attenuation in Schwannoma Tumors Stimulates Growth by Upregulating Three Oncogenic Signaling Pathways. <i>Cancer Research</i> , 2011, 71, 852-861.	0.9	142
77	Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21. <i>Cell Reports</i> , 2019, 28, 3105-3119.e7.	6.4	142
78	Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. <i>Annals of Neurology</i> , 1990, 27, 114-120.	5.3	141
79	TorsinA. <i>Neuron</i> , 2001, 31, 9-12.	8.1	136
80	Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. <i>Annals of Neurology</i> , 1999, 46, 761-769.	5.3	135
81	Impaired Motor Learning in Mice Expressing TorsinA with the DYT1 Dystonia Mutation. <i>Journal of Neuroscience</i> , 2005, 25, 5351-5355.	3.6	134
82	Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates. <i>American Journal of Human Genetics</i> , 2004, 74, 1064-1073.	6.2	133
83	An experimental model of retrovirus gene therapy for malignant brain tumors. <i>Journal of Neurosurgery</i> , 1993, 79, 104-110.	1.6	132
84	Viral vectors for therapy of neurologic diseases. <i>Neuropharmacology</i> , 2017, 120, 63-80.	4.1	130
85	Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. <i>Cellular and Molecular Neurobiology</i> , 1993, 13, 503-515.	3.3	128
86	Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. <i>Oncogene</i> , 2003, 22, 6865-6872.	5.9	128
87	Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7271-7276.	7.1	127
88	A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress. <i>PLoS ONE</i> , 2007, 2, e571.	2.5	123
89	Structural Features of Human Monoamine Oxidase A Elucidated from cDNA and Peptide Sequences. <i>Journal of Neurochemistry</i> , 1988, 51, 1321-1324.	3.9	118
90	Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in <i>TAF1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11020-E11028.	7.1	118

#	ARTICLE	IF	CITATIONS
91	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	5.1	116
92	Expression of the early-onset torsion dystonia gene (DYT1) in human brain. <i>Annals of Neurology</i> , 1998, 43, 669-673.	5.3	111
93	TorsinA in PC12 cells: Localization in the endoplasmic reticulum and response to stress. <i>Journal of Neuroscience Research</i> , 2003, 72, 158-168.	2.9	111
94	Dopamine release is impaired in a mouse model of DYT1 dystonia. <i>Journal of Neurochemistry</i> , 2007, 102, 783-788.	3.9	111
95	Extracellular Vesicles and Their Convergence with Viral Pathways. <i>Advances in Virology</i> , 2012, 2012, 1-12.	1.1	111
96	A Close Association of TorsinA and α -Synuclein in Lewy Bodies. <i>American Journal of Pathology</i> , 2001, 159, 339-344.	3.8	110
97	Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. <i>Journal of Neurosurgery</i> , 1993, 78, 267-273.	1.6	109
98	Functional Coexpression of HSV-1 Thymidine Kinase and Green Fluorescent Protein: Implications for Noninvasive Imaging of Transgene Expression. <i>Neoplasia</i> , 1999, 1, 154-161.	5.3	109
99	Differences in A and B forms of monoamine oxidase revealed by limited proteolysis and peptide mapping. <i>Nature</i> , 1979, 281, 692-694.	27.8	108
100	In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. <i>Molecular Therapy</i> , 2005, 11, 926-931.	8.2	105
101	Metabolic biotinylation of cell surface receptors for in vivo imaging. <i>Nature Methods</i> , 2006, 3, 391-396.	19.0	105
102	Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. <i>Cell Reports</i> , 2020, 30, 2065-2074.e4.	6.4	105
103	Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. <i>Human Molecular Genetics</i> , 2006, 15, 1355-1364.	2.9	104
104	Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. <i>Neurobiology of Disease</i> , 2006, 22, 98-111.	4.4	103
105	Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism. <i>Genomics</i> , 1988, 3, 53-58.	2.9	102
106	A Novel Method for Imaging Apoptosis Using a Caspase-1 Near-Infrared Fluorescent Probe. <i>Neoplasia</i> , 2004, 6, 95-105.	5.3	101
107	Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. <i>Hearing Research</i> , 1999, 134, 1-8.	2.0	99
108	Critical Issues in Gene Therapy for Neurologic Disease. <i>Human Gene Therapy</i> , 2002, 13, 579-604.	2.7	99

#	ARTICLE	IF	CITATIONS
109	TorsinA participates in endoplasmic reticulum-associated degradation. Nature Communications, 2011, 2, 393.	12.8	99
110	Bimodal Viral Vectors and <i>In Vivo</i> Imaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model. Journal of Neuroscience, 2008, 28, 4406-4413.	3.6	98
111	Rapid-onset dystonia-parkinsonism: Linkage to chromosome 19q13. Annals of Neurology, 1999, 46, 176-182.	5.3	97
112	Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2. PLoS ONE, 2011, 6, e16282.	2.5	96
113	Gene Therapy for Brain Tumors. Brain Pathology, 1995, 5, 345-381.	4.1	93
114	Brain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System. Cellular and Molecular Neurobiology, 2011, 31, 949-959.	3.3	93
115	The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Human Molecular Genetics, 2010, 19, 3502-3515.	2.9	92
116	Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy. Cancer Research, 2004, 64, 3236-3242.	0.9	91
117	Differences in the Structure of A and B Forms of Human Monoamine Oxidase. Journal of Neurochemistry, 1981, 37, 363-372.	3.9	90
118	HSV-1 Amplicon Vectors—Simplicity and Versatility. Molecular Therapy, 2000, 2, 9-15.	8.2	88
119	Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. Cellular and Molecular Neurobiology, 2016, 36, 417-427.	3.3	87
120	Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours. Journal of Extracellular Vesicles, 2019, 8, 1588555.	12.2	86
121	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Cancer Research, 2016, 76, 2876-2881.	0.9	85
122	Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat. NeuroReport, 1995, 6, 669-672.	1.2	82
123	Molecular pathways in dystonia. Neurobiology of Disease, 2011, 42, 136-147.	4.4	81
124	Îµ-sarcoglycan mutations found in combination with other dystonia gene mutations. Annals of Neurology, 2002, 52, 675-679.	5.3	80
125	The Early Onset Dystonia Protein TorsinA Interacts with Kinesin Light Chain 1. Journal of Biological Chemistry, 2004, 279, 19882-19892.	3.4	80
126	Molecular Genetics of the Monoamine Oxidases. Journal of Neurochemistry, 1989, 53, 12-18.	3.9	79

#	ARTICLE	IF	CITATIONS
127	Secretion and Uptake of α -Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology, 2018, 38, 1539-1550.	3.3	79
128	Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Movement Disorders, 1994, 9, 305-310.	3.9	75
129	Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology, 2016, 36, 459-470.	3.3	75
130	Mutations in the Norrie disease gene. Human Mutation, 1995, 5, 285-292.	2.5	74
131	Single-Step Conversion of Cells to Retrovirus Vector Producers with Herpes Simplex Virus- α Epstein-Barr Virus Hybrid Amplicons. Journal of Virology, 1999, 73, 10426-10439.	3.4	74
132	Characterization of single microvesicles in plasma from glioblastoma patients. Neuro-Oncology, 2019, 21, 606-615.	1.2	72
133	Glioblastoma hijacks microglial gene expression to support tumor growth. Journal of Neuroinflammation, 2020, 17, 120.	7.2	71
134	Gene Therapy for the Nervous System: Challenges and New Strategies. Neurotherapeutics, 2014, 11, 817-839.	4.4	70
135	New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol. Human Gene Therapy, 1998, 9, 1261-1273.	2.7	69
136	Precise Genetic Mapping and Haplotype Analysis of the Familial Dysautonomia Gene on Human Chromosome 9q31. American Journal of Human Genetics, 1999, 64, 1110-1118.	6.2	69
137	Soluble and Particulate Forms of Rat Catechol-O-Methyltransferase Distinguished by Gel Electrophoresis and Immune Fixation. Journal of Neurochemistry, 1985, 44, 421-432.	3.9	68
138	Benefits and risks of hosting animal cells in the human brain. Nature Medicine, 1997, 3, 964-969.	30.7	68
139	Selective Uptake of Viral and Monocrystalline Particles Delivered Intra-Arterially to Experimental Brain Neoplasms. Human Gene Therapy, 1995, 6, 1543-1552.	2.7	67
140	Fine Localization of the Torsion Dystonia Gene (<i>DYT1</i>) on Human Chromosome 9q34: YAC Map and Linkage Disequilibrium. Genome Research, 1997, 7, 483-494.	5.5	67
141	Extracellular RNA mediates and marks cancer progression. Seminars in Cancer Biology, 2014, 28, 14-23.	9.6	67
142	Structure of the human gene for monoamine oxidase type A. Nucleic Acids Research, 1991, 19, 4537-4541.	14.5	66
143	Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment. Human Gene Therapy, 1996, 7, 1989-1994.	2.7	66
144	Genetic Testing for Early-Onset Torsion Dystonia (<i>DYT1</i>): Introduction of a Simple Screening Method, Experiences from Testing of a Large Patient Cohort, and Ethical Aspects. Genetic Testing and Molecular Biomarkers, 1999, 3, 323-328.	1.7	66

#	ARTICLE	IF	CITATIONS
145	Uptake, functionality, and re-release of extracellular vesicle-encapsulated cargo. Cell Reports, 2022, 39, 110651.	6.4	64
146	Mapping the<i>In Vivo</i>Distribution of Herpes Simplex Virions. Human Gene Therapy, 1998, 9, 1543-1549.	2.7	63
147	Update on herpesvirus amplicon vectors. Molecular Therapy, 2004, 10, 630-643.	8.2	63
148	siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Human Molecular Genetics, 2008, 17, 1436-1445.	2.9	63
149	Genetic therapy for the nervous system. Human Molecular Genetics, 2011, 20, R28-R41.	2.9	62
150	HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part II. Vector Systems and Applications. Neoplasia, 1999, 1, 402-416.	5.3	61
151	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro-Oncology, 2018, 20, 225-235.	1.2	61
152	Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus. Current Gene Therapy, 2004, 4, 385-408.	2.0	61
153	Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research, 2003, 986, 12-21.	2.2	60
154	Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Research, 1994, 658, 219-231.	2.2	59
155	Glial growth factor?like activity in Schwann cell tumors. Annals of Neurology, 1986, 20, 317-322.	5.3	58
156	Monoamine oxidases A and B are differentially regulated by glucocorticoids and ?aging? in human skin fibroblasts. Cellular and Molecular Neurobiology, 1986, 6, 121-150.	3.3	57
157	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i>. Journal of Extracellular Vesicles, 2020, 9, 1689784.	12.2	57
158	Glioblastomas exploit truncated O <i>-</i> linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3693-3703.	7.1	57
159	Receptor Binding Activities of Biotinylated Derivatives of ?-Nerve Growth Factor. Journal of Neurochemistry, 1986, 46, 641-648.	3.9	56
160	Live Visualization of Herpes Simplex Virus Type 1 Compartment Dynamics. Journal of Virology, 2008, 82, 4974-4990.	3.4	55
161	Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. DMM Disease Models and Mechanisms, 2010, 3, 386-396.	2.4	55
162	Properties of monoamine oxidase in control and Lesch-Nyhan fibroblasts. Biochemical Genetics, 1980, 18, 577-590.	1.7	54

#	ARTICLE	IF	CITATIONS
163	Specificity of antisera prepared against pure bovine MAO-B. Brain Research, 1983, 276, 127-139.	2.2	53
164	Î±-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cellular and Molecular Neurobiology, 2016, 36, 437-448.	3.3	53
165	Search for a Founder Mutation in Idiopathic Focal Dystonia from Northern Germany. American Journal of Human Genetics, 1998, 63, 1777-1782.	6.2	52
166	Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms. Human Gene Therapy, 1999, 10, 311-318.	2.7	51
167	In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas. Cancer Research, 2004, 64, 273-278.	0.9	51
168	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles, 2015, 4, 26533.	12.2	51
169	Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. Molecular Therapy, 2015, 23, 824-834.	8.2	51
170	Developmental patterns of torsinA and torsinB expression. Brain Research, 2006, 1073-1074, 139-145.	2.2	47
171	Temperature-Sensitive Divisionless Mutant of <i>Bacillus subtilis</i> Defective in the Initiation of Septation. Journal of Bacteriology, 1973, 113, 985-998.	2.2	47
172	Monoamine oxidase and catechol-O-methyltransferase activities in cultured human skin fibroblasts. Life Sciences, 1976, 19, 1705-1710.	4.3	46
173	MONOAMINE OXIDASE A AND B IN CULTURED CELLS. Journal of Neurochemistry, 1978, 30, 1391-1397.	3.9	46
174	Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy, 2001, 8, 506-511.	4.6	45
175	MONOAMINE OXIDASE ACTIVITY IN NORMAL and LESCH-NYHAN FIBROBLASTS. Journal of Neurochemistry, 1978, 31, 1247-1254.	3.9	44
176	Monoamine oxidase type a in fibroblasts from patients with bipolar depressive illness. Psychiatry Research, 1980, 2, 307-314.	3.3	42
177	Gesicles: Microvesicle “Cookies” for Transient Information Transfer Between Cells. Molecular Therapy, 2011, 19, 1574-1576.	8.2	42
178	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Annals of Neurology, 2000, 47, 369-373.	5.3	41
179	HSV-1 Virions Engineered for Specific Binding to Cell Surface Receptors. Molecular Therapy, 2004, 9, 419-427.	8.2	41
180	Extracellular Vesicle-Mediated Bilateral Communication between Glioblastoma and Astrocytes. Trends in Neurosciences, 2021, 44, 215-226.	8.6	41

#	ARTICLE	IF	CITATIONS
181	Uptake and binding of dopamine and 6-hydroxydopamine in murine neuroblastoma and fibroblast cells. <i>Biochemical Pharmacology</i> , 1976, 25, 383-388.	4.4	39
182	Preventing Growth of Brain Tumors by Creating a Zone of Resistance. <i>Molecular Therapy</i> , 2008, 16, 1695-1702.	8.2	39
183	Noninvasive In Vivo Monitoring of Extracellular Vesicles. <i>Methods in Molecular Biology</i> , 2014, 1098, 249-258.	0.9	39
184	A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. <i>Neurogenetics</i> , 2003, 4, 199-205.	1.4	38
185	TorsinB - perinuclear location and association with torsinA. <i>Journal of Neurochemistry</i> , 2004, 89, 1186-1194.	3.9	38
186	Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. <i>Nature Communications</i> , 2018, 9, 3906.	12.8	38
187	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 255-268.e6.	6.4	38
188	Genetics of Primary Dystonia. <i>Seminars in Neurology</i> , 1999, 19, 271-280.	1.4	37
189	Clinical and genetic evaluation of a family with a mixed dystonia phenotype from south tyrol. <i>Annals of Neurology</i> , 1998, 44, 394-398.	5.3	36
190	Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex Virus in Murine Models of Neurofibromatosis Type 2. <i>Human Gene Therapy</i> , 2006, 17, 20-30.	2.7	36
191	Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 451-62.	2.4	36
192	HSV-1-Based Vectors for Gene Therapy of Neurological Diseases and Brain Tumors: Part I. HSV-1 Structure, Replication and Pathogenesis. <i>Neoplasia</i> , 1999, 1, 387-401.	5.3	35
193	Monoamine oxidase (MAO) activity as a determinant in human neurophysiology. <i>Behavior Genetics</i> , 1982, 12, 53-68.	2.1	34
194	A Novel "Piggyback"™ Packaging System for Herpes Simplex Virus Amplicon Vectors. <i>Human Gene Therapy</i> , 1996, 7, 2003-2013.	2.7	34
195	Neurotransmitter metabolism in murine neuroblastoma cells. <i>Life Sciences</i> , 1976, 18, 267-278.	4.3	33
196	Monoamine oxidase and catechol-o-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome. <i>Psychiatry Research</i> , 1980, 2, 187-197.	3.3	33
197	Targeted Integration of Functional Human ATM cDNA Into Genome Mediated by HSV/AAV Hybrid Amplicon Vector. <i>Molecular Therapy</i> , 2008, 16, 81-88.	8.2	33
198	Î2-Galactosidase Gene Mutations in Patients With Slowly Progressive GM1 Gangliosidosis. <i>Journal of Child Neurology</i> , 1997, 12, 242-247.	1.4	32

#	ARTICLE	IF	CITATIONS
199	Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. <i>Neuro-Oncology</i> , 2016, 18, now099.	1.2	32
200	Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women. <i>Cell Reports Medicine</i> , 2020, 1, 100013.	6.5	32
201	Authentic and artifactual detection of the <i>E. coli</i> lacZ gene product in the rat brain by histochemical methods. <i>Molecular Brain Research</i> , 1992, 16, 311-315.	2.3	31
202	Herpes Vector-Mediated Delivery of Marker Genes to Disseminated Central Nervous System Tumors. <i>Human Gene Therapy</i> , 1996, 7, 291-300.	2.7	31
203	Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. <i>Molecular and Cellular Neurosciences</i> , 2004, 27, 417-426.	2.2	30
204	Relationship Between Platelet Monoamine Oxidase B Activity and Alleles at the MAOB Locus. <i>Journal of Neurochemistry</i> , 1992, 59, 2063-2066.	3.9	30
205	Mutational analysis of the human MAOA gene. <i>American Journal of Medical Genetics Part A</i> , 1996, 67, 92-97.	2.4	29
206	Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. <i>Cancer Gene Therapy</i> , 1999, 6, 14-20.	4.6	29
207	Localized catecholamine storage associated with granules in murine neuroblastoma cells. <i>Brain Research</i> , 1975, 92, 237-256.	2.2	28
208	THE CATECHOL ESTROGEN, 2-HYDROXYESTRADIOL, INHIBITS CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN NEUROBLASTOMA CELLS. <i>Journal of Neurochemistry</i> , 1978, 31, 245-250.	3.9	28
209	Herpes Simplex Virus Type 1 Amplicon Vector-Mediated Gene Transfer to Muscle. <i>Human Gene Therapy</i> , 2002, 13, 261-273.	2.7	28
210	In vivo tomographic imaging of red-shifted fluorescent proteins. <i>Biomedical Optics Express</i> , 2011, 2, 887.	2.9	28
211	Screen for MAOA mutations in target human groups. <i>American Journal of Medical Genetics Part A</i> , 1999, 88, 25-28.	2.4	27
212	Hybrid vector designs to control the delivery, fate and expression of transgenes. <i>Journal of Gene Medicine</i> , 2000, 2, 395-408.	2.8	27
213	Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. <i>Movement Disorders</i> , 2002, 17, 424-426.	3.9	27
214	LONG-TERM EXPRESSION OF THE GENE ENCODING GREEN FLUORESCENT PROTEIN IN MURINE HEMATOPOIETIC CELLS USING RETROVIRAL GENE TRANSFER1. <i>Transplantation</i> , 1998, 65, 1233-1240.	1.0	27
215	Targeting of Liposomes to Cells Bearing Nerve Growth Factor Receptors Mediated by Biotinylated Nerve Growth Factor. <i>Journal of Neurochemistry</i> , 1987, 48, 865-875.	3.9	26
216	Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. <i>Journal of Neuroscience Methods</i> , 2002, 121, 211-219.	2.5	26

#	ARTICLE	IF	CITATIONS
217	New insights and updated guidelines for epigenome-wide association studies. <i>Neuroepigenetics</i> , 2015, 1, 14-19.	2.8	26
218	Dopamine transmission in DYT1 dystonia. <i>Advances in Neurology</i> , 2004, 94, 53-60.	0.8	26
219	Dexamethasone selectively increases monoamine oxidase type a in human skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1981, 98, 836-843.	2.1	25
220	Differences in the structures of monoamine oxidases A and B in rat clonal cell lines. <i>Biochemical Pharmacology</i> , 1983, 32, 441-448.	4.4	25
221	Biochemical and Cellular Analysis of Human Variants of the DYT1 Dystonia Protein, TorsinA/TOR1A. <i>Human Mutation</i> , 2014, 35, 1101-1113.	2.5	25
222	Linkage Analysis in a Family with Dominantly Inherited Torsion Dystonia: Exclusion of the Pro-Opiomelanocortin and Glutamic Acid Decarboxylase Genes and Other Chromosomal Regions Using DNA Polymorphisms. <i>Journal of Neurogenetics</i> , 1986, 3, 159-175.	1.4	24
223	Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. <i>Molecular Therapy</i> , 2003, 7, 790-800.	8.2	24
224	Gene transfer into the nervous system. <i>Molecular Neurobiology</i> , 1987, 1, 339-371.	4.0	23
225	Targeting gene therapy vectors to CNS malignancies. <i>Journal of NeuroVirology</i> , 1998, 4, 133-147.	2.1	23
226	Potentiated Gene Delivery to Tumors Using Herpes Simplex Virus/Epstein-Barr Virus/RV Tribrid Amplicon Vectors. <i>Human Gene Therapy</i> , 2003, 14, 611-626.	2.7	23
227	Untethering the Nuclear Envelope and Cytoskeleton: Biologically Distinct Dystonias Arising from a Common Cellular Dysfunction. <i>International Journal of Cell Biology</i> , 2012, 2012, 1-18.	2.5	23
228	Neural Precursor Cells and Their Role in Neuro-Oncology. <i>Developmental Neuroscience</i> , 2004, 26, 118-130.	2.0	22
229	Animal models for drug discovery in dystonia. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 83-97.	5.0	22
230	dtorsin, the Drosophila Ortholog of the Early-Onset Dystonia TOR1A (DYT1), Plays a Novel Role in Dopamine Metabolism. <i>PLoS ONE</i> , 2011, 6, e26183.	2.5	22
231	Glioma EVs Contribute to Immune Privilege in the Brain. <i>Trends in Cancer</i> , 2019, 5, 393-396.	7.4	22
232	Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. <i>Journal of Neurosurgery</i> , 1997, 87, 89-95.	1.6	21
233	RNAi blocks DYT1 mutant torsinA inclusions in neurons. <i>Neuroscience Letters</i> , 2006, 395, 201-205.	2.1	21
234	Regression of Schwannomas Induced by Adeno-Associated Virus-Mediated Delivery of Caspase-1. <i>Human Gene Therapy</i> , 2013, 24, 152-162.	2.7	21

#	ARTICLE	IF	CITATIONS
235	RESERPINE SENSITIVITY OF CATECHOLAMINE METABOLISM IN MURINE NEUROBLASTOMA CLONE N1E-115. Journal of Neurochemistry, 1975, 25, 877-882.	3.9	20
236	Combining CNS transplantation and gene transfer. Neurobiology of Aging, 1989, 10, 647-648.	3.1	20
237	The role of "tumor suppressor"™ genes in neural tumors. Trends in Neurosciences, 1990, 13, 3-6.	8.6	20
238	A genetic linkage map of human chromosome 9q. Genomics, 1992, 14, 715-720.	2.9	20
239	Dynamics of Transgene Expression in Human Glioblastoma Cells Mediated by Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors. Human Gene Therapy, 2002, 13, 2147-2159.	2.7	20
240	miRNA signature of schwannomas: Possible role(s) of "tumor suppressor"•miRNAs in benign tumors. Oncotarget, 2011, 2, 265-270.	1.8	20
241	Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. Journal of Gene Medicine, 1999, 1, 176-185.	2.8	19
242	HSV Amplicon Vectors for Cancer Therapy. Current Gene Therapy, 2006, 6, 361-370.	2.0	19
243	Mutant Sodium Channel for Tumor Therapy. Molecular Therapy, 2009, 17, 810-819.	8.2	18
244	<sc><i>TAF1</i></sc> Transcripts and Neurofilament Light Chain as Biomarkers for X-linked Dystonia-Parkinsonism. Movement Disorders, 2021, 36, 206-215.	3.9	18
245	[¹⁸ F]â€Dopa positron emission tomography imaging in earlyâ€stage, nonâ€parkin juvenile parkinsonism. Movement Disorders, 2002, 17, 789-794.	3.9	17
246	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy - Methods and Clinical Development, 2019, 15, 18-26.	4.1	17
247	Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles. Scientific Reports, 2019, 9, 17387.	3.3	17
248	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances, 2021, 7, .	10.3	17
249	Tyrosine-dependent increase of tyrosine hydroxylase in neuroblastoma cells. Nature, 1974, 252, 719-720.	27.8	16
250	Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Molecular Brain Research, 2002, 101, 132-135.	2.3	16
251	Stochastic Model of Tsc1 Lesions in Mouse Brain. PLoS ONE, 2013, 8, e64224.	2.5	16
252	High-Affinity [3H]Choline Accumulation in Cultured Human Skin Fibroblasts. Journal of Neurochemistry, 1981, 36, 746-752.	3.9	15

#	ARTICLE	IF	CITATIONS
253	The Autosomal Dominant Dystonias. Brain Pathology, 1992, 2, 297-308.	4.1	15
254	A novel imaging-compatible sciatic nerve schwannoma model. Journal of Neuroscience Methods, 2011, 195, 75-77.	2.5	15
255	New methods for investigation of neuronal migration in embryonic brain explants. Journal of Neuroscience Methods, 2015, 239, 80-84.	2.5	15
256	A comparison of the proliferative and replicative life span kinetics of cell cultures derived from monozygotic twins. In Vitro, 1981, 17, 20-27.	1.2	14
257	Correction of Acidbeta-Galactosidase Deficiency in GM1Gangliosidosis Human Fibroblasts by Retrovirus VectorMediated Gene Transfer: Higher Efficiency of Release and Cross-Correction by the Murine Enzyme. Human Gene Therapy, 2000, 11, 715-727.	2.7	14
258	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease, 2015, 82, 22-31.	4.4	14
259	CRISPR-Cas knockout of miR21 reduces glioma growth. Molecular Therapy - Oncolytics, 2022, 25, 121-136.	4.4	14
260	TRANSPORT OF TYROSINE, PHENYLALANINE, TRYPTOPHAN AND GLYCINE IN NEUROBLASTOMA CLONES. Journal of Neurochemistry, 1977, 28, 127-135.	3.9	13
261	Catechol-O-methyltransferase activity in cultured human skin fibroblasts from controls and patients with dystonia musculorum deformans. Journal of Neuroscience Research, 1981, 6, 349-360.	2.9	13
262	Characterization of monoamine oxidase activity during early stages of quail embryogenesis. International Journal of Developmental Neuroscience, 1983, 1, 49-57.	1.6	13
263	HSV-1 amplicon peptide display vector. Journal of Virological Methods, 2003, 107, 71-79.	2.1	13
264	Microfluidic platform to evaluate migration of cells from patients with DYT1 dystonia. Journal of Neuroscience Methods, 2014, 232, 181-188.	2.5	13
265	Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo. Biomaterials, 2022, 281, 121366.	11.4	13
266	Phenylalanine hydroxylase in melanoma cells. Journal of Cellular Physiology, 1978, 94, 307-314.	4.1	12
267	Artifactual presence of β -nerve growth factor in adult mouse brain. Brain Research, 1984, 295, 35-40.	2.2	12
268	Co-factor insufficiency in Dystonia-Parkinsonian syndrome. Nature Genetics, 1994, 8, 207-208.	21.4	12
269	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. Molecular Therapy, 2013, 21, 266-268.	8.2	12
270	Living Proof of Activity of Extracellular Vesicles in the Central Nervous System. International Journal of Molecular Sciences, 2021, 22, 7294.	4.1	12

#	ARTICLE	IF	CITATIONS
271	Neurotransmitter metabolism in cell culture. <i>Biochemical Pharmacology</i> , 1976, 25, 2337-2342.	4.4	11
272	The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene. <i>Genomics</i> , 1995, 25, 730-732.	2.9	11
273	[34] HSV-1 amplicon vectors. <i>Methods in Enzymology</i> , 2002, 346, 593-603.	1.0	11
274	Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. <i>Movement Disorders</i> , 2004, 19, 845-847.	3.9	11
275	Exosome/microvesicle content is altered in leucine-rich repeat kinase 2 mutant induced pluripotent stem cell-derived neural cells. <i>Journal of Comparative Neurology</i> , 2020, 528, 1203-1215.	1.6	11
276	Linkage analysis in juvenile neuronal ceroid lipofuscinosis. <i>American Journal of Medical Genetics Part A</i> , 1992, 42, 542-545.	2.4	10
277	Virus vectors for gene delivery to the nervous system. <i>Restorative Neurology and Neuroscience</i> , 1995, 8, 21-34.	0.7	10
278	GlioM&M: Web-based tool for studying circulating and infiltrating monocytes and macrophages in glioma. <i>Scientific Reports</i> , 2020, 10, 9898.	3.3	10
279	AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice. <i>Experimental Animals</i> , 2021, 70, 450-458.	1.1	10
280	Exclusion of p75NGFR and other candidate genes in a family with hereditary sensory neuropathy Type II. <i>Pain</i> , 1996, 67, 135-139.	4.2	9
281	Versatile Role of Rab27a in Glioma: Effects on Release of Extracellular Vesicles, Cell Viability, and Tumor Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 554649.	3.5	9
282	Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins. <i>Communications Biology</i> , 2022, 5, 485.	4.4	9
283	Distinct forms of monoamine oxidase expressed in hepatoma and HeLa cells in culture. <i>Biochemical Pharmacology</i> , 1979, 28, 525-528.	4.4	8
284	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. <i>Molecular Therapy</i> , 2016, 24, S226-S227.	8.2	8
285	Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 1-12.	5.1	8
286	Differences in monoamine oxidase activity between cultured noradrenergic and cholinergic sympathetic neurons. <i>Developmental Biology</i> , 1987, 120, 305-308.	2.0	7
287	Isolation of the mRNA encoding rat liver catechol-O-methyltransferase. <i>Biochemical and Biophysical Research Communications</i> , 1989, 158, 776-782.	2.1	7
288	Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. <i>Scientific Reports</i> , 2018, 8, 2324.	3.3	7

#	ARTICLE	IF	CITATIONS
289	Oncogenes in neural tumors. Trends in Neurosciences, 1986, 9, 150-155.	8.6	6
290	Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia. Human Genetics, 1991, 87, 311-316.	3.8	6
291	Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra. Restorative Neurology and Neuroscience, 1995, 8, 59-61.	0.7	6
292	Peripherin gene is linked to keratin 18 gene on human chromosome 12. Somatic Cell and Molecular Genetics, 1995, 21, 83-88.	0.7	6
293	TorsinA and early-onset torsion dystonia. Advances in Neurology, 2004, 94, 87-93.	0.8	6
294	Models for Inherited Susceptibility to Cancer in the Nervous System: A Molecular-Genetic Approach to Neurofibromatosis. Developmental Neuroscience, 1987, 9, 144-153.	2.0	5
295	Magnetic Resonance Imaging and Characterization of Spontaneous Lesions in a Transgenic Mouse Model of Tuberous Sclerosis as a Model for Endothelial Cell-Based Transgene Delivery. Human Gene Therapy, 2005, 16, 1367-1376.	2.7	5
296	Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. Annals of Neurology, 2000, 48, 65-71.	5.3	5
297	Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy - Methods and Clinical Development, 2022, , .	4.1	5
298	Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells. Cellular and Molecular Neurobiology, 1981, 1, 351-359.	3.3	4
299	Healing Genes in the Nervous System. Neuron, 2010, 68, 178-181.	8.1	4
300	Dopa-Responsive Dystonia: Functional Analysis of Single Nucleotide Substitutions within the 5' UTR of GCH1. PLoS ONE, 2013, 8, e76975.	2.5	4
301	Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in <i>Drosophila melanogaster</i> . Biology Open, 2015, 4, 585-595.	1.2	4
302	Expression of monoamine oxidase A and B activities in mouse cybrids and hybrids. Life Sciences, 1981, 28, 425-432.	4.3	3
303	Biological Gene-Product Delivery to the Brain: A Protocol for Retroviral Gene Transfer into Cultured Cells and Intracerebral Transplantation. Methods, 1993, 3, 63-68.	0.5	3
304	Refocus the Recombinant DNA Advisory Committee. Nature Medicine, 2012, 18, 1007-1007.	30.7	3
305	Do DNA rearrangements occur in neuronal development? Clues from an inherited human disease. Trends in Neurosciences, 1983, 6, 444-446.	8.6	2
306	TorsinA and DYT1 early-onset dystonia. Future Neurology, 2008, 3, 61-72.	0.5	2

#	ARTICLE	IF	CITATIONS
307	Genetic Evaluation in Primary Dystonia. Medical Psychiatry, 2006, , 21-44.	0.2	2
308	Herpes Virus Vectors. , 2002, , 201-233.		1
309	438. Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells. Molecular Therapy, 2006, 13, S168.	8.2	1
310	Tannous et al. Respond:. Molecular Therapy, 2009, 17, 1311-1312.	8.2	1
311	The ASGCT in 2012: Charting a Path to Bring Novel Biologic Therapies to the Clinic. Molecular Therapy, 2012, 20, 1289-1290.	8.2	1
312	TMIC-28. GLIOBLASTOMA EXPLOITS CELL SURFACE GLYCOSYLATION-MEDIATED IMMUNE REGULATORY CIRCUITS FOR IMMUNE ESCAPE. Neuro-Oncology, 2018, 20, vi262-vi262.	1.2	1
313	Application of HSV-1 Vectors to the Treatment of Cancer. , 0, , 19-53.		1
314	DYT1 Transgenic Mouse. , 2005, , 287-292.		1
315	Biotinylated ?-Nerve Growth Factor Binds to PC12 Cells. Annals of the New York Academy of Sciences, 1986, 463, 214-216.	3.8	0
316	956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod Gaussia princeps. Molecular Therapy, 2006, 13, S369.	8.2	0
317	635. Mechanisms of Caspase-1 Mediated Schwannoma Regression. Molecular Therapy, 2015, 23, S252.	8.2	0
318	Long-term therapeutic efficacy of intravenous AAV-mediated hamartin replacement in mouse model of tuberous sclerosis type 1. IBRO Reports, 2019, 6, S504.	0.3	0
319	OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, ii7-ii7.	0.7	0